Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab

Retina

Volumn 34, Issue 12, 2014, Pages 2439-2443

  Eadie, James A ^a   Ip, Michael S ^a   Kulkarni, Amol D ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Aflibercept; CRVO; Intravitreal pharmacotherapy; Macular edema

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; DRUG EFFICACY; EVIDENCE BASED PRACTICE; FEMALE; HUMAN; MACULAR EDEMA; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; REPEATED DRUG DOSE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG EFFECTS; DRUG SUBSTITUTION; INTRAVITREAL DRUG ADMINISTRATION; RETINAL VEIN OCCLUSION;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG SUBSTITUTION; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84916596593     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000238     Document Type: Article

References (11)

1. Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127:1101-1114.
2. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, shamcontrolled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-1146.
3. Brown DM, Campochiaro PA, Singh RP, et al. Ranubizumab for macular edema following central retinal vein occlusion: sixmonth primary end point results of a phase III study. Ophthalmology 2010;117:1124-1133.e1.
4. Brown DM, Heier J, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 2013;155:429-437.
5. Spaide R, Chang L, Klancnik J, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. AM J Ophthalmol 2009;147:298-306.
6. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 2009;93:452-456.
7. Zhang H, Liu Z, Sun P, et al. Intravitreal bevacizumab for treatment of macular edema secondary to retinal vein occlusion: eighteen-month results of a prospective trial. J Ocul Pharmacol Ther 2011;27:615-621.
8. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranubizumab and bevacizumab. Angiogenesis 2012;15:171-185.
9. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002;99:11393-11398.
10. Xiaoyan D, Jianqing L, Xuting H, et al. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina 2011;31:838-845.
11. Mayer W, Remy M, Wolf A, et al. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema. Ophthalmologica 2012;228: 110-116.